News

Hemanext Announces Partnership with Aplastic Anemia & MDS International Foundation

Hemanext Inc. (“Hemanext” or the “Company”), a leading innovator in blood processing, storage, and transfusion technology, is proud to announce a new partnership with The Aplastic Anemia & MDS International Foundation (“AAMDS”), the world’s leading nonprofit health organization dedicated to supporting patients living with aplastic anemia, myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases.

Patients living with these conditions can develop anemia, which can cause severe fatigue and other symptoms, and many require regular blood transfusions.1 Health experts estimate that, annually in the United States, between 10,000 and 40,000 patients are diagnosed with MDS2, between 600-900 are diagnosed with Aplastic anemia, and around 500 are diagnosed with PNH.3

AAMDS is a patient centric organization that funds research for treatments and cures, develops education and peer programs, and organizes impactful conferences that facilitate an exchange of knowledge. Hemanext will work with the organization to advance the AAMDS mission of providing answers, support, and hope to thousands of patients and their families living with bone marrow failure diseases.

Hemanext Vice President of Marketing Alex Marichal said: “We are proud to partner with an organization like AAMDS that is on the front lines helping patients who live with these challenging diseases. Our mission at Hemanext is to improve the quality, safety, and cost of transfusion therapy, and we are excited to become part of this community of support, as we work to enhance the lives of these patients.”

Janice Frey-Angel, CEO of AAMDSIF (Aplastic Anemia & MDS International Foundation) said “As a patient-focused organization, AAMDS commends the work of companies like Hemanext that are developing resources and technologies that could aid patients living with chronic blood disorders. Our partnership with Hemanext will focus on how innovations like the Hemanext technology have the potential to lessen the load of those who require regular transfusions.”

About Hemanext

Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs). The company’s aim is to significantly improve the quality of stored RBCs by limiting oxygen and carbon dioxide levels in the storage environment.

Hemanext Media Contact
Nathan Riggs / Hallie Wolff
nathan.riggs@kekstcnc.com / Hallie.Wolff@kekstcnc.com

Stacy Smith
Associate Director Marketing Communications
stacy.smith@hemanext.com

  1. ScienceDirect. “Erythropoiesis stimulating agents and other growth factors in low-risk MDS.” https://doi.org/10.1016/j.beha.2013.09.007. Accessed October 2020
  2. R. Bejar, D. Steensma, “Recent developments in myelodysplastic syndromes.” Blood. 2014; 124(18); 2793-2803.
  3. AAMDS International Foundation (n.d.). FAQs. Retrieved January 22, 2022, from https://www.aamds.org/education/faq
Previous
Next

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us